You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNizatidine
Accession NumberDB00585  (APRD00706)
TypeSmall Molecule
GroupsApproved
DescriptionA histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. [PubChem]
Structure
Thumb
Synonyms
Nizatidina
Nizatidine
Nizatidinum
External Identifiers
  • LY-139037
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AxidCapsule150 mgOralPendopharm Division Of De Pharmascience Inc1988-12-31Not applicableCanada
AxidCapsule300 mgOralPendopharm Division Of De Pharmascience Inc1988-12-31Not applicableCanada
Dom-nizatidine 150mg CapsulesCapsule150 mgOralDominion Pharmacal2001-10-31Not applicableCanada
Gen-nizatidineCapsule150 mgOralGenpharm Ulc2002-07-122010-08-04Canada
Gen-nizatidineCapsule300 mgOralGenpharm Ulc2002-07-122010-08-04Canada
Nizatidine-150Capsule150 mgOralPro Doc Limitee2001-02-122010-07-13Canada
Nizatidine-300Capsule300 mgOralPro Doc Limitee2001-02-122010-07-13Canada
Novo-nizatidineCapsule300 mgOralNovopharm Limited1999-07-23Not applicableCanada
Novo-nizatidineCapsule150 mgOralNovopharm Limited1999-07-23Not applicableCanada
Nu-nizatidineCapsule150 mgOralNu Pharm IncNot applicableNot applicableCanada
Nu-nizatidineCapsule300 mgOralNu Pharm IncNot applicableNot applicableCanada
PHL-nizatidineCapsule150 mgOralPharmel Inc1999-03-012016-10-25Canada
PHL-nizatidineCapsule300 mgOralPharmel Inc1999-03-012016-10-25Canada
PMS-nizatidineCapsule300 mgOralPharmascience Inc1998-04-28Not applicableCanada
PMS-nizatidine 150mg CapsulesCapsule150 mgOralPharmascience Inc1998-04-28Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nizatidineCapsule300 mgOralApotex Inc1998-12-31Not applicableCanada
Apo-nizatidineCapsule150 mgOralApotex Inc1998-12-31Not applicableCanada
NizatidineCapsule300 mg/1OralDr Reddy's Laboratories Limited2005-09-15Not applicableUs
NizatidineCapsule150 mg/1OralA S Medication Solutions2011-07-15Not applicableUs
NizatidineCapsule150 mg/1Oralnizatidine2010-01-14Not applicableUs
NizatidineCapsule150 mg/1OralGlenmark Generics Inc.,USA2011-07-15Not applicableUs
NizatidineCapsule150 mg/1Oralbryant ranch prepack2005-09-15Not applicableUs
NizatidineCapsule150 mg/1OralMylan Pharmaceuticals Inc.2002-07-10Not applicableUs
NizatidineCapsule150 mg/1OralMedsource Pharmaceuticals2011-07-15Not applicableUs
NizatidineCapsule150 mg/1OralLake Erie Medical DBA Quality Care Products LLC2002-07-09Not applicableUs
NizatidineCapsule300 mg/1OralRebel Distributors Corp2002-07-09Not applicableUs
NizatidineCapsule300 mg/1OralGlenmark Generics Inc.,USA2011-07-15Not applicableUs
NizatidineSolution15 mg/mLOralAmneal Pharmaceuticals2009-12-14Not applicableUs
NizatidineCapsule300 mg/1OralMylan Pharmaceuticals Inc.2002-07-10Not applicableUs
NizatidineCapsule150 mg/1OralH.J. Harkins Company, Inc.2002-07-09Not applicableUs
NizatidineCapsule150 mg/1OralEon Labs, Inc.2002-07-05Not applicableUs
NizatidineCapsule150 mg/1OralProficient Rx LP2011-07-15Not applicableUs
NizatidineCapsule150 mg/1OralActavis Pharma, Inc.2002-07-09Not applicableUs
NizatidineCapsule150 mg/1OralRebel Distributors Corp2002-07-05Not applicableUs
NizatidineCapsule150 mg/1OralPreferred Pharmaceuticals Inc.2015-08-28Not applicableUs
NizatidineCapsule150 mg/1OralPreferred Pharmaceuticals, Inc2012-03-29Not applicableUs
NizatidineCapsule150 mg/1OralCarilion Materials Management2002-07-09Not applicableUs
NizatidineCapsule300 mg/1OralEon Labs, Inc.2002-07-05Not applicableUs
NizatidineCapsule150 mg/1OralDr Reddy's Laboratories Limited2005-09-15Not applicableUs
NizatidineCapsule300 mg/1Oralbryant ranch prepack2005-09-15Not applicableUs
NizatidineCapsule300 mg/1OralActavis Pharma, Inc.2002-07-09Not applicableUs
NizatidineCapsule150 mg/1OralRebel Distributors Corp2002-07-09Not applicableUs
NizatidineCapsule300 mg/1OralDispensing Solutions Inc.2009-01-22Not applicableUs
Nizatidine SolutionSolution15 mg/mLOralGemini Laboratories, LLC2016-08-12Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Axid ArTablet, film coated75 mg/1OralPfizer Consumer Healthcare1996-05-09Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
AcinonNot Available
TazacEli Lilly
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIP41PML4GHR
CAS number76963-41-2
WeightAverage: 331.45
Monoisotopic: 331.113667284
Chemical FormulaC12H21N5O2S2
InChI KeySGXXNSQHWDMGGP-UHFFFAOYSA-N
InChI
InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3
IUPAC Name
dimethyl[(4-{[(2-{[1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}-1,3-thiazol-2-yl)methyl]amine
SMILES
CNC(NCCSCC1=CSC(CN(C)C)=N1)=C[N+]([O-])=O
Pharmacology
IndicationFor the treatment of acid-reflux disorders (GERD), peptic ulcer disease, active benign gastric ulcer, and active duodenal ulcer.
Structured Indications
PharmacodynamicsNizatidine is a competitive, reversible inhibitor of histamine at the histamine H2-receptors, particularly those in the gastric parietal cells. By inhibiting the action of histamine on stomach cells, nizatidine reduces stomach acid production. Nizatidine had no demonstrable antiandrogenic action. Full-dose therapy for the problems treated by nizatidine lasts no longer than 8 weeks. It has been demonstrated that treatment with a reduced dose of nizatidine is effective as maintenance therapy following healing of active duodenal ulcers.
Mechanism of actionNizatidine competes with histamine for binding at the H2-receptors on the gastric basolateral membrane of parietal cells. Competitive inhibition results in reduction of basal and nocturnal gastric acid secretions. The drug also decreases the gastric acid response to stimuli such as food, caffeine, insulin, betazole, or pentagastrin.
TargetKindPharmacological actionActionsOrganismUniProt ID
Histamine H2 receptorProteinyes
antagonist
HumanP25021 details
Related Articles
AbsorptionRapid (bioavailability of nizatidine exceeds 70%)
Volume of distribution
  • 0.8 to 1.5 L/kg
Protein binding35%
Metabolism

Hepatic. Less than 7% of an oral dose is metabolized as N2-monodes-methylnizatidine, an H2-receptor antagonist, which is the principal metabolite excreted in the urine. Other likely metabolites are the N2-oxide (less than 5% of the dose) and the S-oxide (less than 6% of the dose).

SubstrateEnzymesProduct
Nizatidine
Not Available
N2-monodes-methylnizatidineDetails
Route of eliminationNot Available
Half life1-2 hours
Clearance
  • 40-60 L/h
  • 7 – 14 L/h [functionally anephric patients]
ToxicityOral, rat LD50: 301 mg/kg. Symptoms of overdose include cholinergic-type effects including lacrimation, salivation, emesis, miosis, and diarrhea.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Nizatidine Action PathwayDrug actionSMP00233
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Nizatidine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Nizatidine.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Nizatidine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Nizatidine.Experimental, Illicit
AcetaminophenThe serum concentration of Nizatidine can be increased when it is combined with Acetaminophen.Approved
AfatinibThe serum concentration of Nizatidine can be increased when it is combined with Afatinib.Approved
AlbendazoleThe serum concentration of Nizatidine can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Nizatidine can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Nizatidine can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Nizatidine can be increased when it is combined with Alfentanil.Approved, Illicit
AmantadineThe serum concentration of Nizatidine can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Nizatidine can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe serum concentration of Nizatidine can be decreased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Nizatidine can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Nizatidine can be increased when it is combined with Amlodipine.Approved
AmphetamineAmphetamine may decrease the sedative activities of Nizatidine.Approved, Illicit
AmprenavirThe serum concentration of Nizatidine can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Nizatidine can be increased when it is combined with Amsacrine.Approved
AstemizoleThe serum concentration of Nizatidine can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Nizatidine.Approved, Investigational
AtenololThe serum concentration of Nizatidine can be increased when it is combined with Atenolol.Approved
AtorvastatinThe serum concentration of Nizatidine can be increased when it is combined with Atorvastatin.Approved
AzelastineThe serum concentration of Nizatidine can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Nizatidine can be increased when it is combined with Azithromycin.Approved
BenzocaineThe serum concentration of Nizatidine can be increased when it is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Nizatidine.Approved, Illicit
Benzylpenicilloyl PolylysineNizatidine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe serum concentration of Nizatidine can be increased when it is combined with Bepridil.Approved, Withdrawn
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Nizatidine.Approved
BiperidenThe serum concentration of Nizatidine can be increased when it is combined with Biperiden.Approved
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Nizatidine.Approved
BromocriptineThe serum concentration of Nizatidine can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Nizatidine can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Nizatidine can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Nizatidine can be increased when it is combined with Cabazitaxel.Approved
CaffeineThe serum concentration of Nizatidine can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Nizatidine can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Nizatidine can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Nizatidine can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Nizatidine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarvedilolThe serum concentration of Nizatidine can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Nizatidine can be increased when it is combined with Caspofungin.Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Nizatidine.Approved
CefpodoximeNizatidine can cause a decrease in the absorption of Cefpodoxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
CefuroximeNizatidine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ChloroquineThe serum concentration of Nizatidine can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Nizatidine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Nizatidine can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Nizatidine can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Nizatidine can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Nizatidine can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Nizatidine can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Nizatidine can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Nizatidine can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Nizatidine can be increased when it is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe serum concentration of Nizatidine can be increased when it is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Nizatidine can be increased when it is combined with Clarithromycin.Approved
ClofazimineThe serum concentration of Nizatidine can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Nizatidine can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe serum concentration of Nizatidine can be decreased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Nizatidine can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Nizatidine can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Nizatidine can be increased when it is combined with Colforsin.Experimental
CrizotinibThe serum concentration of Nizatidine can be increased when it is combined with Crizotinib.Approved
CyclophosphamideThe serum concentration of Nizatidine can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Nizatidine can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Nizatidine.Approved, Investigational
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Nizatidine.Approved
DaclatasvirThe serum concentration of Nizatidine can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Nizatidine can be increased when it is combined with Dactinomycin.Approved
DasatinibNizatidine can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DaunorubicinThe serum concentration of Nizatidine can be decreased when it is combined with Daunorubicin.Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Nizatidine.Approved
DesipramineThe serum concentration of Nizatidine can be increased when it is combined with Desipramine.Approved
DesloratadineThe serum concentration of Nizatidine can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Nizatidine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmethylphenidateNizatidine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Nizatidine.Approved, Illicit
DextromethorphanThe serum concentration of Nizatidine can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Nizatidine can be increased when it is combined with Diclofenac.Approved, Vet Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Nizatidine.Approved, Illicit
DigoxinThe serum concentration of Nizatidine can be decreased when it is combined with Digoxin.Approved
DihydroergotamineThe serum concentration of Nizatidine can be increased when it is combined with Dihydroergotamine.Approved
DiltiazemThe serum concentration of Nizatidine can be increased when it is combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Nizatidine can be increased when it is combined with Dipyridamole.Approved
DoxazosinThe serum concentration of Nizatidine can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Nizatidine can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Nizatidine can be decreased when it is combined with Doxorubicin.Approved, Investigational
DronabinolThe serum concentration of Nizatidine can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Nizatidine can be increased when it is combined with Dronedarone.Approved
ElbasvirThe serum concentration of Nizatidine can be increased when it is combined with Elbasvir.Approved
EnalaprilThe serum concentration of Nizatidine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Nizatidine can be increased when it is combined with Enzalutamide.Approved
ErgonovineThe serum concentration of Nizatidine can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Nizatidine can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Nizatidine.Approved, Investigational
ErythromycinThe serum concentration of Nizatidine can be decreased when it is combined with Erythromycin.Approved, Vet Approved
EstramustineThe serum concentration of Nizatidine can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Nizatidine can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Nizatidine can be decreased when it is combined with Estrone.Approved
EtoposideThe serum concentration of Nizatidine can be increased when it is combined with Etoposide.Approved
EtravirineThe serum concentration of Nizatidine can be increased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Nizatidine can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Nizatidine can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
Ferric CarboxymaltoseNizatidine can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateNizatidine can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateNizatidine can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FexofenadineThe serum concentration of Nizatidine can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Nizatidine can be increased when it is combined with Fidaxomicin.Approved
FluconazoleThe serum concentration of Nizatidine can be increased when it is combined with Fluconazole.Approved
FluoxetineThe serum concentration of Nizatidine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Nizatidine can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Nizatidine can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Nizatidine can be increased when it is combined with Flurazepam.Approved, Illicit
FluvoxamineThe serum concentration of Nizatidine can be increased when it is combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Nizatidine.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Nizatidine.Approved, Investigational
GenisteinThe serum concentration of Nizatidine can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Nizatidine can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Nizatidine can be increased when it is combined with Glycerol.Experimental
Gramicidin DThe serum concentration of Nizatidine can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe serum concentration of Nizatidine can be increased when it is combined with Grepafloxacin.Withdrawn
HaloperidolThe serum concentration of Nizatidine can be increased when it is combined with Haloperidol.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Nizatidine.Approved, Investigational
HydrocortisoneThe serum concentration of Nizatidine can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Nizatidine.Approved
IdelalisibThe serum concentration of Nizatidine can be increased when it is combined with Idelalisib.Approved
ImatinibThe serum concentration of Nizatidine can be increased when it is combined with Imatinib.Approved
ImipramineThe serum concentration of Nizatidine can be increased when it is combined with Imipramine.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Nizatidine.Approved
IndomethacinThe serum concentration of Nizatidine can be increased when it is combined with Indomethacin.Approved, Investigational
IronNizatidine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranNizatidine can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateNizatidine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoniumThe serum concentration of Nizatidine can be increased when it is combined with Isavuconazonium.Approved, Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Nizatidine.Approved, Investigational
IvacaftorThe serum concentration of Nizatidine can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Nizatidine can be increased when it is combined with Ivermectin.Approved, Vet Approved
KetamineThe serum concentration of Nizatidine can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Nizatidine.Approved, Investigational
KetoconazoleThe serum concentration of Nizatidine can be increased when it is combined with Ketoconazole.Approved, Investigational
LansoprazoleThe serum concentration of Nizatidine can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Nizatidine can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Nizatidine.Approved
LevofloxacinThe serum concentration of Nizatidine can be increased when it is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Nizatidine can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Nizatidine can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Nizatidine can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Nizatidine can be decreased when it is combined with Liotrix.Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Nizatidine.Approved, Investigational
LisinoprilThe serum concentration of Nizatidine can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Nizatidine can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Nizatidine can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Nizatidine can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Nizatidine can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Nizatidine can be increased when it is combined with Losartan.Approved
LovastatinThe serum concentration of Nizatidine can be increased when it is combined with Lovastatin.Approved, Investigational
LumacaftorThe serum concentration of Nizatidine can be decreased when it is combined with Lumacaftor.Approved
MaprotilineThe serum concentration of Nizatidine can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Nizatidine can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Nizatidine can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Nizatidine can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MephedroneMephedrone may decrease the sedative activities of Nizatidine.Investigational
MephentermineMephentermine may decrease the sedative activities of Nizatidine.Approved
MeprobamateThe serum concentration of Nizatidine can be increased when it is combined with Meprobamate.Approved, Illicit
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Nizatidine.Approved
MethadoneThe serum concentration of Nizatidine can be increased when it is combined with Methadone.Approved
MethamphetamineMethamphetamine may decrease the sedative activities of Nizatidine.Approved, Illicit
MethylphenidateNizatidine can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MetoprololThe serum concentration of Nizatidine can be increased when it is combined with Metoprolol.Approved, Investigational
MibefradilThe serum concentration of Nizatidine can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Nizatidine can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Nizatidine can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Nizatidine can be decreased when it is combined with Mifepristone.Approved, Investigational
MitomycinThe serum concentration of Nizatidine can be increased when it is combined with Mitomycin.Approved
MitoxantroneThe serum concentration of Nizatidine can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MMDAMMDA may decrease the sedative activities of Nizatidine.Experimental, Illicit
MorphineThe serum concentration of Nizatidine can be increased when it is combined with Morphine.Approved, Investigational
NaltrexoneThe serum concentration of Nizatidine can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Nizatidine can be increased when it is combined with Naringenin.Experimental
NefazodoneThe serum concentration of Nizatidine can be decreased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Nizatidine.Approved
NeostigmineThe serum concentration of Nizatidine can be increased when it is combined with Neostigmine.Approved, Vet Approved
NicardipineThe serum concentration of Nizatidine can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Nizatidine can be decreased when it is combined with Nifedipine.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Nizatidine.Approved, Investigational
NisoldipineThe serum concentration of Nizatidine can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Nizatidine can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Nizatidine can be increased when it is combined with Nitrendipine.Approved
NorethisteroneThe serum concentration of Nizatidine can be decreased when it is combined with Norethisterone.Approved
OmeprazoleThe serum concentration of Nizatidine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
P-NitrophenolThe serum concentration of Nizatidine can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Nizatidine can be increased when it is combined with Paclitaxel.Approved, Vet Approved
Palmitic AcidThe serum concentration of Nizatidine can be increased when it is combined with Palmitic Acid.Experimental
PantoprazoleThe serum concentration of Nizatidine can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Nizatidine can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Nizatidine.Approved
PerindoprilThe serum concentration of Nizatidine can be increased when it is combined with Perindopril.Approved
PhenobarbitalThe serum concentration of Nizatidine can be decreased when it is combined with Phenobarbital.Approved
PhenterminePhentermine may decrease the sedative activities of Nizatidine.Approved, Illicit
PimozideThe serum concentration of Nizatidine can be increased when it is combined with Pimozide.Approved
Platelet Activating FactorThe serum concentration of Nizatidine can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Nizatidine can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Nizatidine.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Nizatidine can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Nizatidine can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Nizatidine can be increased when it is combined with Prednisone.Approved, Vet Approved
ProbenecidThe serum concentration of Nizatidine can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Nizatidine can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Nizatidine can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Nizatidine can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Nizatidine can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Nizatidine can be increased when it is combined with Protriptyline.Approved
PseudoephedrinePseudoephedrine may decrease the sedative activities of Nizatidine.Approved
QuercetinThe serum concentration of Nizatidine can be increased when it is combined with Quercetin.Experimental
QuinacrineThe serum concentration of Nizatidine can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Nizatidine can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Nizatidine can be increased when it is combined with Quinine.Approved
RanitidineThe serum concentration of Nizatidine can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Nizatidine can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Nizatidine can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Nizatidine can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Nizatidine can be decreased when it is combined with Reserpine.Approved
RifampicinThe serum concentration of Nizatidine can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Nizatidine.Approved
RisedronateThe serum concentration of Risedronate can be increased when it is combined with Nizatidine.Approved, Investigational
RitobegronRitobegron may decrease the sedative activities of Nizatidine.Investigational
RitonavirThe serum concentration of Nizatidine can be decreased when it is combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Nizatidine can be increased when it is combined with Rolapitant.Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Nizatidine.Approved, Investigational
ScopolamineThe serum concentration of Nizatidine can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Nizatidine can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertralineThe serum concentration of Nizatidine can be increased when it is combined with Sertraline.Approved
SimeprevirThe serum concentration of Nizatidine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Nizatidine can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Nizatidine can be decreased when it is combined with Sirolimus.Approved, Investigational
SorafenibThe serum concentration of Nizatidine can be increased when it is combined with Sorafenib.Approved, Investigational
SpironolactoneThe serum concentration of Nizatidine can be increased when it is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Nizatidine can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Nizatidine can be increased when it is combined with Staurosporine.Experimental
StreptozocinThe serum concentration of Nizatidine can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Nizatidine can be increased when it is combined with Sulfinpyrazone.Approved
SumatriptanThe serum concentration of Nizatidine can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Nizatidine can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Nizatidine can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Nizatidine can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Nizatidine can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Nizatidine can be increased when it is combined with Taurocholic Acid.Experimental
TelmisartanThe serum concentration of Nizatidine can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Nizatidine can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Nizatidine can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Nizatidine can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Nizatidine can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Nizatidine can be increased when it is combined with Testosterone.Approved, Investigational
TicagrelorThe serum concentration of Nizatidine can be increased when it is combined with Ticagrelor.Approved
TolvaptanThe serum concentration of Nizatidine can be increased when it is combined with Tolvaptan.Approved
TrazodoneThe serum concentration of Nizatidine can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Nizatidine can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Nizatidine can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Nizatidine can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Nizatidine can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Nizatidine can be increased when it is combined with Troleandomycin.Approved
VareniclineThe serum concentration of Varenicline can be increased when it is combined with Nizatidine.Approved, Investigational
VenlafaxineThe serum concentration of Nizatidine can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Nizatidine can be decreased when it is combined with Verapamil.Approved
VinblastineThe serum concentration of Nizatidine can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Nizatidine can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Nizatidine can be increased when it is combined with Vinorelbine.Approved, Investigational
ZimelidineThe serum concentration of Nizatidine can be increased when it is combined with Zimelidine.Withdrawn
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Do not take Aluminum or magnesium antacids or supplements while on this medication.
  • May take Vitamin D.
  • No iron, zinc or fluoride within 2 hours of taking this medication.
  • Take without regard to meals.
References
Synthesis Reference

Charles W. Ryan, Bruce A. Slomski, “Synthesis of nizatidine intermediate.” U.S. Patent US4777260, issued June, 1983.

US4777260
General ReferencesNot Available
External Links
ATC CodesA02BA04
AHFS Codes
  • 56:28.12
PDB EntriesNot Available
FDA labelDownload (380 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9572
Blood Brain Barrier+0.5
Caco-2 permeable-0.589
P-glycoprotein substrateSubstrate0.8357
P-glycoprotein inhibitor INon-inhibitor0.8947
P-glycoprotein inhibitor IINon-inhibitor0.8861
Renal organic cation transporterNon-inhibitor0.7832
CYP450 2C9 substrateNon-substrate0.8108
CYP450 2D6 substrateNon-substrate0.6721
CYP450 3A4 substrateNon-substrate0.5916
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8508
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7826
Ames testNon AMES toxic0.6129
CarcinogenicityNon-carcinogens0.9182
BiodegradationNot ready biodegradable0.9295
Rat acute toxicity2.4350 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.6244
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Smithkline beecham corp dba glaxosmithkline
  • Apotex inc
  • Dr reddys laboratories ltd
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Braintree laboratories inc
  • Amneal pharmaceuticals
  • Wyeth consumer healthcare
Packagers
Dosage forms
FormRouteStrength
CapsuleOral300 mg
Tablet, film coatedOral75 mg/1
CapsuleOral150 mg
CapsuleOral150 mg/1
CapsuleOral300 mg/1
SolutionOral15 mg/mL
Prices
Unit descriptionCostUnit
Axid 300 mg pulvule6.0USD each
Nizatidine 300 mg capsule4.97USD capsule
Axid 300 mg Capsule3.98USD capsule
Axid 150 mg pulvule3.62USD each
Nizatidine 150 mg capsule2.48USD capsule
Axid 150 mg Capsule2.06USD capsule
Apo-Nizatidine 300 mg Capsule0.96USD capsule
Novo-Nizatidine 300 mg Capsule0.96USD capsule
Pms-Nizatidine 300 mg Capsule0.96USD capsule
Axid 15 mg/ml Solution0.84USD ml
Nizatidine 15 mg/ml Solution0.76USD ml
Apo-Nizatidine 150 mg Capsule0.53USD capsule
Gen-Nizatidine 150 mg Capsule0.53USD capsule
Novo-Nizatidine 150 mg Capsule0.53USD capsule
Pms-Nizatidine 150 mg Capsule0.53USD capsule
Axid ar 75 mg tablet0.3USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6930119 No2002-07-172022-07-17Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point130-132 °CPhysProp
water solubility10-33mg/mLNot Available
logP1.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0386 mg/mLALOGPS
logP0.7ALOGPS
logP0.77ChemAxon
logS-3.9ALOGPS
pKa (Strongest Basic)6.54ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area83.33 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity95.84 m3·mol-1ChemAxon
Polarizability35.54 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 2,4-disubstituted thiazoles. These are compounds containing a thiazole ring substituted at the positions 2 and 3.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassThiazoles
Direct Parent2,4-disubstituted thiazoles
Alternative Parents
Substituents
  • 2,4-disubstituted 1,3-thiazole
  • Aralkylamine
  • Heteroaromatic compound
  • C-nitro compound
  • Tertiary amine
  • Tertiary aliphatic amine
  • Organic nitro compound
  • Organic oxoazanium
  • Thioether
  • Sulfenyl compound
  • Allyl-type 1,3-dipolar organic compound
  • Propargyl-type 1,3-dipolar organic compound
  • Organic 1,3-dipolar compound
  • Dialkylthioether
  • Azacycle
  • Organic oxide
  • Amine
  • Organic zwitterion
  • Organic oxygen compound
  • Organic nitrogen compound
  • Organonitrogen compound
  • Organosulfur compound
  • Organic salt
  • Hydrocarbon derivative
  • Organopnictogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) si...
Gene Name:
HRH2
Uniprot ID:
P25021
Molecular Weight:
40097.65 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Enriz RD, Jauregui EA: [Theoretical conformation study of tiotidine and nizatidine, two strong histamine H2-receptor antagonists]. Acta Cient Venez. 1991;42(2):70-6. [PubMed:1843561 ]
  3. Meredith CG, Speeg KV Jr, Schenker S: Nizatidine, a new histamine H2-receptor antagonist, and hepatic oxidative drug metabolism in the rat: a comparison with structurally related compounds. Toxicol Appl Pharmacol. 1985 Feb;77(2):315-24. [PubMed:2858133 ]
  4. Lin TM, Evans DC, Warrick MW, Pioch RP: Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs. J Pharmacol Exp Ther. 1986 Nov;239(2):406-10. [PubMed:2877081 ]
  5. Okabe S, Takeuchi K, Okada M, Kumadaki Y, Nakata M, Nakata H: [Effects of nizatidine, a new histamine H2-receptor antagonist, on gastric acid secretion and various gastric and duodenal lesions in rats: comparison with cimetidine]. Nihon Yakurigaku Zasshi. 1989 Mar;93(3):133-44. [PubMed:2567267 ]
  6. Kounenis G, Koutsoviti-Papadopoulou M, Elezoglou V: The excitatory effect of the new histamine H2-receptor antagonist nizatidine (LY 139037) on the guinea pig ileum. J Pharmacobiodyn. 1987 Nov;10(11):669-72. [PubMed:2895808 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Laine-Cessac P, Turcant A, Premel-Cabic A, Boyer J, Allain P: Inhibition of cholinesterases by histamine 2 receptor antagonist drugs. Res Commun Chem Pathol Pharmacol. 1993 Feb;79(2):185-93. [PubMed:8095733 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Dahan A, Sabit H, Amidon GL: The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. AAPS J. 2009 Jun;11(2):205-13. doi: 10.1208/s12248-009-9092-5. Epub 2009 Mar 25. [PubMed:19319690 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 05, 2016 02:42